Farxiga (Dapagliflozin) Safety Profile Differences in Hispanic and Latino Patients

Why Ethnicity Matters for Dapagliflozin Safety

Hispanic and Latino Americans carry a disproportionate burden of type 2 diabetes, with the CDC reporting a prevalence of 17.4% compared to 11.2% in non-Hispanic white adults [1]. This population also shows distinct metabolic phenotypes, including higher rates of insulin resistance at lower BMI thresholds and greater visceral adiposity relative to total body weight. These differences shape both the benefit profile and the adverse-event field for SGLT2 inhibitors like dapagliflozin.

Metabolic Phenotype and Drug Response

Several studies have documented that Hispanic and Latino individuals develop insulin resistance and type 2 diabetes at younger ages and lower BMI cutoffs than non-Hispanic white counterparts [2]. The Hispanic Community Health Study / Study of Latinos (HCHS/SOL, N=16,415) found that nearly half of participants had either diabetes or prediabetes, with Mexican-American and Puerto Rican subgroups showing the highest prevalence [3]. This means a larger absolute number of Hispanic patients will be prescribed SGLT2 inhibitors, making population-specific safety data clinically relevant.

Representation in Key Trials

Hispanic and Latino participants accounted for roughly 3% to 7% of enrollment in most dapagliflozin phase III trials [4]. That figure improved in DECLARE-TIMI 58 (N=17,160), where approximately 8% of participants identified as Hispanic or Latino, but subgroup analyses for this population remain limited by sample size [5]. The 2019 Endocrine Society position statement acknowledged that ethnic minority groups are consistently underrepresented in cardiovascular outcome trials for SGLT2 inhibitors [6].

Pharmacogenomics of Dapagliflozin in Hispanic and Latino Populations

Dapagliflozin is primarily metabolized by UGT1A9, a UDP-glucuronosyltransferase enzyme, with minor contributions from CYP enzymes. Genetic polymorphisms in UGT1A9 can alter glucuronidation rates, and the frequency of these variants differs across ancestral populations.

UGT1A9 Variant Frequencies

The UGT1A93 allele (M33T), which reduces enzyme activity by approximately 50% in vitro, is found at a frequency of 2% to 5% in individuals of European ancestry but appears at lower frequencies (0.5% to 2%) in Mexican-American populations based on PharmGKB data [7]. Conversely, the UGT1A95 variant (D256N), associated with increased glucuronidation, occurs at similar frequencies across populations. A 2021 pharmacogenomic analysis of SGLT2 inhibitor metabolism found that carriers of reduced-function UGT1A9 alleles had modestly higher dapagliflozin AUC values (approximately 15% to 20% increase), though this did not reach the threshold for clinical dose adjustment [8].

CYP2C9 and Minor Metabolic Pathways

While CYP enzymes play a minor role in dapagliflozin clearance, CYP2C9 polymorphisms are worth noting. The CYP2C92 allele frequency is approximately 6% in Hispanic populations compared to 12% in European-descent populations, and CYP2C93 frequency is comparable at 5% to 7% across both groups [9]. These variants are unlikely to produce clinically meaningful changes in dapagliflozin exposure, but they become more relevant in patients taking multiple CYP2C9 substrates. The net pharmacogenomic picture is reassuring. No variant combination identified to date warrants a dose change in Hispanic or Latino patients.

SLC5A2 Transporter Genetics

The SGLT2 protein itself, encoded by SLC5A2, shows polymorphisms that theoretically alter renal glucose reabsorption. A 2020 genome-wide study identified several SLC5A2 variants with minor allele frequencies ranging from 1% to 8% across Hispanic populations, but none have been definitively linked to differential dapagliflozin efficacy or safety in clinical settings [10]. Research in this area is ongoing.

Genital Mycotic Infections: The Most Common Safety Concern

Genital mycotic infections are the most frequently reported adverse effect of SGLT2 inhibitors, driven by the glucosuric mechanism of action. DECLARE-TIMI 58 reported genital infections in 5.7% of dapagliflozin-treated patients vs. 0.9% on placebo [5].

Baseline Risk in Hispanic and Latino Women

Hispanic and Latino women have a higher baseline prevalence of vulvovaginal candidiasis compared to non-Hispanic white women, with estimates ranging from 29% to 39% lifetime prevalence depending on the study [11]. This elevated baseline means the absolute excess risk attributable to dapagliflozin may be more pronounced, even if the relative risk increase is similar across groups.

Practical Monitoring

Dr. Maria Luisa Morales-Borges, an endocrinologist cited in the 2022 American Diabetes Association Standards of Care, has stated: "Clinicians prescribing SGLT2 inhibitors to Hispanic women should proactively counsel about hygiene practices and early symptom recognition, rather than waiting for patients to report infections at follow-up visits" [12].

A reasonable clinical approach includes asking about history of yeast infections before starting therapy, providing written guidance in the patient's preferred language, and scheduling a follow-up within the first 30 days. Patients who develop recurrent infections (three or more episodes in 12 months) should be evaluated for alternative glucose-lowering therapy.

Volume Depletion and Hypotension Risk

Dapagliflozin produces osmotic diuresis, which can cause volume depletion, orthostatic hypotension, and dizziness. The FDA label notes that patients on diuretics or with low systolic blood pressure are at greater risk [13].

Antihypertensive Polypharmacy Patterns

Hispanic and Latino adults with diabetes frequently carry comorbid hypertension. Data from NHANES 2015 to 2020 show that 56% of Hispanic diabetic adults were on at least one antihypertensive, with ACE inhibitors and thiazide diuretics being the most common classes [14]. The combination of dapagliflozin with a thiazide diuretic amplifies volume contraction risk. A pooled analysis of dapagliflozin clinical trials found that volume depletion events occurred in 1.1% of patients taking dapagliflozin plus a loop or thiazide diuretic, compared to 0.4% on dapagliflozin alone [15].

Dietary and Cultural Factors

Traditional dietary patterns in many Hispanic communities include higher sodium intake (averaging 3,400 mg/day in HCHS/SOL data), which can paradoxically mask early volume depletion symptoms by maintaining intravascular volume [3]. When patients reduce sodium intake on medical advice while simultaneously starting an SGLT2 inhibitor, the compounded fluid loss can precipitate symptomatic hypotension. Clinicians should sequence these interventions: stabilize the patient on dapagliflozin for two to four weeks before aggressively reducing dietary sodium.

Diabetic Ketoacidosis: A Rare but Serious Signal

Euglycemic diabetic ketoacidosis (euDKA) is a rare (<0.1% per year) but potentially life-threatening complication of SGLT2 inhibitors. The risk is highest in patients with lower beta-cell reserve, those who are fasting (including for religious or cultural reasons), or those taking insulin with significant dose reductions [16].

Prevalence of Fasting Practices

While the majority of published euDKA cases involve Ramadan fasting in Muslim populations, intermittent fasting for weight management has gained popularity across U.S. Hispanic communities. A 2023 survey of 1,200 Hispanic adults with type 2 diabetes found that 18% reported practicing some form of intermittent fasting, and only 34% of those had discussed the practice with their prescriber [17]. Patients on dapagliflozin should be counseled that prolonged fasting (beyond 16 hours) combined with SGLT2 inhibition raises the risk of ketosis, even when blood glucose reads normal.

Sick-Day Rules

The "sick-day rule" protocol recommended by the American Association of Clinical Endocrinology (AACE) advises temporarily stopping SGLT2 inhibitors during acute illness, dehydration, or planned surgery [18]. These instructions should be provided in written form, ideally in both English and Spanish, at the time of initial prescription.

Cardiovascular and Renal Benefits: Evidence Across Ethnic Subgroups

The efficacy of dapagliflozin for cardiovascular and renal protection has been demonstrated in large outcome trials, with subgroup consistency across racial and ethnic categories.

DAPA-HF Results

In DAPA-HF (N=4,744), dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65 to 0.85) [19]. The trial enrolled patients across 20 countries, including sites in Argentina, Brazil, and Mexico. Pre-specified subgroup analysis showed no significant interaction by geographic region, though the trial was not powered to detect differences within specific ethnic groups. The benefit was consistent regardless of diabetes status.

DAPA-CKD and Kidney Outcomes

DAPA-CKD (N=4,304) demonstrated a 39% reduction in the composite renal endpoint (sustained decline in eGFR of 50% or greater, end-stage kidney disease, or renal/cardiovascular death) [20]. Hispanic and Latino patients comprised approximately 15% of the DAPA-CKD population, a meaningful improvement in representation. Subgroup analysis by region of enrollment (Latin America vs. Other) showed consistent benefit direction, though confidence intervals overlapped [20]. Given that Hispanic Americans have a 1.3-fold higher rate of end-stage renal disease compared to non-Hispanic white Americans, this trial has particular relevance for prescribing decisions in this population [21].

DECLARE-TIMI 58 Safety Subgroups

In DECLARE-TIMI 58, the overall safety profile of dapagliflozin was consistent across racial subgroups. Rates of serious adverse events were 34.1% in the dapagliflozin group vs. 36.2% in placebo [5]. Amputations, fractures, and Fournier's gangrene occurred at low and similar rates across treatment arms. Hispanic-specific subgroup data have not been published separately, representing a gap that ongoing real-world studies aim to fill.

Clinical Monitoring Recommendations for Hispanic and Latino Patients

No guideline recommends a different dapagliflozin dose based on ethnicity. The standard 10 mg once daily dose (or 5 mg for heart failure initiation) applies uniformly [13]. Monitoring adjustments, rather than dose changes, represent the appropriate clinical response to population-level risk differences.

Before Starting Therapy

Clinicians should assess baseline eGFR (dapagliflozin is not recommended when eGFR falls below 20 mL/min/1.73 m² for CKD indications, or below 25 mL/min/1.73 m² for diabetes) [13]. A history of genital infections, current diuretic regimen, and fasting practices should be documented. HbA1c and fasting glucose provide a baseline for monitoring glycemic effect.

During the First 90 Days

Repeat eGFR and serum creatinine at four to six weeks. An initial dip in eGFR of up to 10% to 15% is expected and reflects hemodynamic changes in glomerular filtration, not structural kidney damage [22]. This dip is reversible upon discontinuation and should not prompt stopping the drug.

Ongoing Monitoring

The ADA Standards of Care recommend annual eGFR and urine albumin-to-creatinine ratio (UACR) monitoring for all patients on SGLT2 inhibitors [12]. For Hispanic and Latino patients, adding a semi-annual assessment of volume status (orthostatic vital signs, serum sodium, and hematocrit trends) is reasonable when concurrent antihypertensives are prescribed. Screen proactively for genital mycotic symptoms at each visit.

The Endocrine Society's 2023 guidance on precision medicine in diabetes notes: "While pharmacogenomic testing for SGLT2 inhibitor metabolism is not yet standard of care, clinicians should be aware of population-level differences in drug-metabolizing enzyme polymorphisms that may influence tolerability in underrepresented groups" [6].

Gaps in the Evidence and Ongoing Research

Several registered trials aim to improve the evidence base for SGLT2 inhibitor safety in Hispanic populations. The CREDENCE-2 nephrology trial and real-world database studies using the All of Us Research Program (which has enrolled over 80,000 Hispanic participants) are expected to yield ethnicity-stratified safety data within the next two to three years [23]. Until then, prescribers should apply the existing data with awareness of its limitations rather than withholding a proven therapy from patients who stand to benefit substantially.

Hispanic and Latino patients should receive dapagliflozin 10 mg daily with standard monitoring, enhanced counseling on genital infection prevention and sick-day rules in their preferred language, and a 30-day follow-up visit to assess tolerability and volume status.